

- VI. Claim 19, in so far as it is drawn to a method of contacting cell or tissue culture cells with an antagonist of unknown composition, class and subclass unclassifiable.
- VII. Claim 20, drawn to a method of screening for a compound which blocks interaction of a polypeptide with a receptor, comprising contacting said compound to said polypeptide in the presence of said receptor, classified in class 436, subclass 501, for example.

Applicants provisionally elect Group I, Claims 1-6, drawn to polypeptides, classified in class 530, subclass 350, as discussed in the present Restriction Requirement. Applicants note that two Group VI appear in the Restriction Requirement, and that the actual number of groups is seven.

The Examiner further restricted Groups I-IV and VII as follows:

- A. Human DAP 12.
- B. Rodent DAP 12.
- C. Human DAP10.
- D. Mouse DAP10.
- E. Human MDL-1.
- F. Mouse MDL-1

Applicants hereby select "E", human MDL-1, with traverse. Applicants submit that human and mouse MDL-1 have substantial amino acid identity as demonstrated by the alignment comparison provided on page 15, of the specification. Mouse and human MDL-1 possess greater than 130 out 190 identical amino acid residues (~68%). Searching both proteins should not be a burden on the Examiner. Applicants respectfully request reconsideration of this restriction requirement.

Applicants will address the issue of inventorship for the elected claims and amend inventorship appropriately if the elected restriction is made final.

Applicants reserve the right to file subsequent applications claiming the non-elected subject matter and do not waive any of their rights or abandon any non-elected subject matter. Since Applicants have fully and completely responded to the Restriction

Requirement and have made the required election, this application is now in order for early action.

If the Examiner believes that a telephone conference would aid the prosecution of this case in any way, please call the undersigned.

Applicant believes that no additional fees are due with this communication. Should this not be the case, the Commissioner is hereby authorized to debit any charges or refund any overpayments to DNAX Deposit Account No. 04-1239.

Respectfully submitted,

Date: 05-Sept-2006

By: Sheela Mohan-Peterson  
Sheela Mohan-Peterson,  
Reg. No. 41,201  
Attorney for Applicants

**Customer No. 028008**  
DNAX Research, Inc.  
901 California Avenue  
Palo Alto, CA 94304-1104  
Telephone (Switchboard): (650) 496-6400  
Telephone No. (Direct): (650) 496-1244  
Facsimile No.: (650) 496-1200